Combating Endocrine Resistance in Breast Cancer With Novel Agents, Combinations

Video

This video reviews endocrine resistance mediated by CDK4/6, FGFR, and PI3K in HR-positive breast cancer, and highlights the latest efforts to inhibit these pathways with novel targeted drugs and combinations.

In this video, Steffi Oesterreich, PhD, of the University of Pittsburgh Cancer Institute in Pennsylvania, reviews endocrine resistance mediated by CDK4/6, FGFR, and PI3K in hormone receptor (HR)-positive breast cancer, and highlights the latest efforts to inhibit these pathways with novel targeted drugs and combinations.

Oesterreich chaired a spotlight session on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS).

Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content
ESMO 2024 saw a wide range of potentially practice-changing data across multiple oncology disciplines such as the breast cancer and lung cancer fields.

Conference Compendium: The Top 10 Takeaways From ESMO 2024

Russ Conroy
September 18th 2024
Article

ESMO 2024 saw a wide range of potentially practice-changing data across multiple oncology disciplines such as the breast cancer and lung cancer fields.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.

Ribociclib Combo Approved in HR+/HER2- Stage II-III Early Breast Cancer

Ariana Pelosci
September 17th 2024
Article

Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.

Breastfeeding Is Feasible Amid Endocrine Therapy Break in HR+ Breast Cancer

Ariana Pelosci
September 16th 2024
Article

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.

QOL data from DESTINY-Breast06 support T-DXd as a new therapeutic option in previously treated HER2-low and HER2-ultralow metastatic breast cancer.

QOL, Pain Deterioration Improve With T-DXd in HER2-Low Breast Cancer

Jonah Feldman
September 15th 2024
Article

QOL data from DESTINY-Breast06 support T-DXd as a new therapeutic option in previously treated HER2-low and HER2-ultralow metastatic breast cancer.